

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 11)*

Allogene Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)
- ☐ Rule 13d-1(c)
- ☒ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

Arie Belldegrün, M.D.

Check the appropriate box if a member of a Group (see instructions)

2

☐ (a)

☐ (b)

3

Sec Use Only

Citizenship or Place of Organization

4

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power
		4,838,291.00
		Shared Voting Power
	6	8,772,287.00
		Sole Dispositive Power
	7	4,838,291.00
		Shared Dispositive Power
	8	8,772,287.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person	
		13,610,578.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	
		☐
11	Percent of class represented by amount in row (9)	
		3.9 %
12	Type of Reporting Person (See Instructions)	
		IN

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons	
	Bellco Legacy LLC	
	Check the appropriate box if a member of a Group (see instructions)	
2	☐	(a)
	☐	(b)
3	Sec Use Only	
4	Citizenship or Place of Organization	
	DELAWARE	
		Sole Voting Power
	5	0.00
		Shared Voting Power
	6	539,867.00
		Sole Dispositive Power
	7	0.00
		Shared Dispositive Power
	8	539,867.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person	
		539,867.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	
		☐

11 Percent of class represented by amount in row (9)

0.2 %

Type of Reporting Person (See Instructions)

12

OO

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

Bellco Legacy IV LLC

Check the appropriate box if a member of a Group (see instructions)

2

☐ (a)

☐ (b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Sole Voting Power

5

0.00

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:

Shared Voting Power

6

4,710,120.00

Sole Dispositive Power

7

0.00

Shared Dispositive

Power

8

4,710,120.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

4,710,120.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

☐

Percent of class represented by amount in row (9)

11

1.3 %

Type of Reporting Person (See Instructions)

12

OO

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

Vida Ventures LLC

2

Check the appropriate box if a member of a Group (see instructions)

☐ (a)

☐ (b)

3 Sec Use Only
Citizenship or Place of Organization

4 NEVADA

Sole Voting Power

5

0.00

Number of
Shares

Shared Voting Power

6

1,798,163.00

Beneficially
Owned by
Each

Sole Dispositive Power

7

0.00

Reporting
Person

Shared Dispositive

With:

Power

8

1,798,163.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

1,798,163.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

☐

Percent of class represented by amount in row (9)

11

0.5 %

Type of Reporting Person (See Instructions)

12

OO

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

Vida Ventures III, L.P.

Check the appropriate box if a member of a Group (see instructions)

2

☐ (a)

☐ (b)

3 Sec Use Only

Citizenship or Place of Organization

4

NEVADA

Number of
Shares

Sole Voting Power

5

0.00

Beneficially
Owned by

Shared Voting Power

6

1,720,172.00

Each

Sole Dispositive Power

Reporting
Person

0.00

With:

Shared Dispositive

Power

8

	1,720,172.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	1,720,172.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	0.5 %
12	Type of Reporting Person (See Instructions)
	OO

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons
	Vida Ventures III-A, L.P.
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	NEVADA
	Sole Voting Power
5	0.00
	Shared Voting Power
6	3,965.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive
8	Power
	3,965.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	3,965.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	0.0 %
12	Type of Reporting Person (See Instructions)
	OO

SCHEDULE 13G

Item 1.

Name of issuer:

- (a) Allogene Therapeutics, Inc.
Address of issuer's principal executive offices:
- (b) 210 East Grand Avenue, South San Francisco, CA, 94080.

Item 2.

Name of person filing:

- (a) Arie Belldегrun Belco Legacy LLC Belco Legacy IV LLC Vida Ventures LLC Vida Ventures III, L.P. Vida Ventures III-A, L.P.
Address or principal business office or, if none, residence:
- (b) Arie Belldегrun: 10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067 Belco Legacy LLC: 10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067 Belco Legacy IV LLC: 10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067 Vida Ventures LLC: 40 Broad Street, #201, Boston, MA 02109 Vida Ventures III, L.P.: 40 Broad Street, #201, Boston, MA 02109 Vida Ventures III-A, L.P.: 40 Broad Street, #201, Boston, MA 02109
Citizenship:
- (c) Arie Belldегrun: United States and Israel Belco Legacy LLC: Delaware Belco Legacy IV LLC: Delaware Vida Ventures LLC: Nevada Vida Ventures III, L.P.: Nevada Vida Ventures III-A, L.P.: Nevada
Title of class of securities:
- (d) Common Stock
- (e) CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

- (a) Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. Row 9 of Dr. Belldегrun's cover page includes 4,010,524 shares of common stock issuable within 60 days of June 30, 2026 upon the exercise of stock options held by the Reporting Person and also includes (a) 4,710,120 shares of common stock beneficially owned by Belco Legacy IV LLC, a limited liability company managed by Dr. Belldегrun and Rebecka Belldегrun, (b) 539,867 shares of common stock beneficially owned by Belco Legacy LLC, a limited liability company owned and managed by trusts controlled by Dr. Belldегrun and Rebecka Belldегrun, (c) 1,798,163 shares of common stock beneficially owned by Vida Ventures LLC (Vida), a limited liability company of which VV Manager LLC is the manager, of which Dr. Belldегrun is a Senior Managing Director, (d) 1,720,172 shares of common stock beneficially owned by Vida Ventures III, L.P. (Vida III), a limited partnership of which Vida Ventures GP III, LLC (Vida GP III) is the manager, of which Dr. Belldегrun is a Senior Managing Director, and (e) 3,965 shares of common stock beneficially owned by Vida Ventures III-A, L.P. (Vida III-A), a limited partnership of which Vida GP III is the manager, of which Dr. Belldегrun is a Senior Managing Director. Dr. Belldегrun disclaims beneficial ownership of the shares held by Vida, Vida III and Vida III-A, except to the extent of any pecuniary interest therein, and other than for the purpose of determining his obligations under Section 13(d) of the Exchange Act.
- (b) Percent of class:

Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. This percentage is calculated based on 345,154,561 shares of common stock outstanding as of May 11, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed on May 13, 2026. %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

(ii) Shared power to vote or to direct the vote:

Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

(iii) Sole power to dispose or to direct the disposition of:

Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

(iv) Shared power to dispose or to direct the disposition of:

Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

Item 5. Ownership of 5 Percent or Less of a Class.

☒ Ownership of 5 percent or less of a class

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Arie Belldegrün, M.D.

Signature: /s/ Arie Belldegrün

Name/Title: Arie Belldegrün, M.D.

Date: 08/07/2026

Belco Legacy LLC

Signature: /s/ Arie Belldegrün

Name/Title: By Arie Belldegrün, M.D., Manager

Date: 08/07/2026

Belco Legacy IV LLC

Signature: /s/ Arie Belldegrün

Name/Title: By Arie Belldegrün, M.D., Manager

Date: 08/07/2026

Vida Ventures LLC

Signature: /s/ Arie Belldegrün

Name/Title: By VV Manager LLC, its Manager, By Arie
Belldegrün, M.D., Senior Managing Director

Date: 08/07/2026

Vida Ventures III, L.P.

Signature: /s/ Arie Belldegrün

Name/Title: By Vida Ventures GP III, LLC, its Manager, By
Arie Belldegrün, M.D., Senior Managing Director

Date: 08/07/2026

Vida Ventures III-A, L.P.

Signature: /s/ Arie Belldegrün

Name/Title: By Vida Ventures GP III, LLC, its Manager, By
Arie Belldegrün, M.D., Senior Managing
Director,

Date: 08/07/2026

Exhibit Information

Joint Filing Agreement

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common stock of Allogene Therapeutics, Inc., a Delaware corporation, and that this Agreement may be included as an Exhibit to such joint filing. This Agreement may be executed in any number of counterparts all of which, taken together, shall constitute one and the same instrument.

Dated: August 7, 2026

/s/ Arie Belldegrün

Arie Belldegrün, M.D.

Belco Legacy LLC

By: /s/ Arie Belldegrün

Name: Arie Belldegrün, M.D., Manager

Belco Legacy IV LLC

By: /s/ Arie Belldegrün

Name: Arie Belldegrün, M.D., Manager

Vida Ventures LLC

By: VV Manager LLC, its Manager

By: /s/ Arie Belldegrün

Name: Arie Belldegrün, M.D., Senior Managing Director

Vida Ventures III, L.P.

By: Vida Ventures GP III, LLC, its Manager

By: /s/ Arie Belldegrün

Name: Arie Belldegrün, M.D., Senior Managing Director

Vida Ventures III-A, L.P.

By: Vida Ventures GP III, its Manager

By: /s/ Arie Belldegrün

Name: Arie Belldegrün, M.D., Senior Managing Director